Results 91 to 100 of about 3,923 (195)

Meropenem Use and Challenges in Treating Severe Infections in Pakistan Amid Antimicrobial Resistance

open access: yesInterdisciplinary Perspectives on Infectious Diseases, Volume 2026, Issue 1, 2026.
Meropenem is a broad‐spectrum carbapenem antibiotic essential for treating serious infections including urinary tract infections, pneumonia, sepsis, and meningitis. This narrative review examines meropenem resistance trends and prescribing practices for severe infections in Pakistan highlighting how inappropriate use drives local antimicrobial ...
Nasim Akhtar   +7 more
wiley   +1 more source

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study

open access: yesInfection and Drug Resistance, 2022
Raghdaa Shrief,1 Amira H El-Ashry,2 Rasha Mahmoud,3 Rasha El-Mahdy2 1Medical Microbiology and Immunology Department, Faculty of Medicine, Damietta University, Damietta, Egypt; 2Medical Microbiology and Immunology Department, Faculty of Medicine, Mansoura
Shrief R   +3 more
doaj  

VALIDATION OF SIMPLE ISOCRATIC RP-UPLC METHOD FOR MEROPENEM AND VABORBACTAM DETERMINATION AND IT'S APPLICATION IN THE STUDY OF STRESS DEGRADATION

open access: yes, 2018
A simple, Accurate, precise method was developed for the simultaneous estimation of the Meropenem and Vaborbactam in tablet dosage form. Chromatogram was run through SB C8 100 x 3.0 mm, 1.8m.
Sudha Rani Bollimuntha 1 *, Kalyana Seela Kottapalli 2, Bhavya Manda 3
core   +1 more source

Resistance to Ceftazidime/Avibactam Plus Meropenem/Vaborbactam When Both are Used Together Achieved in Four Steps from Metallo-β-Lactamase Negative <i>Klebsiella pneumoniae</i>. [PDF]

open access: yes, 2020
Serine β-lactamases are dominant causes of β-lactam resistance in Klebsiella pneumoniae. Recently, this has driven clinical deployment of the β-lactam/β-lactamase inhibitor pairs ceftazidime/avibactam and meropenem/vaborbactam.
Avison, Matthew B   +3 more
core   +1 more source

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

open access: yes, 2018
Vaborbactam is a member of a new class of β-lactamase inhibitors with inhibitory activity against serine carbapenemases (e.g., Klebsiella pneumoniae carbapenemase) that has been developed in combination with meropenem.
Michael N. Dudley   +5 more
core   +1 more source

Comparisons of vaborbactam-bound PBP3 with the P. aeruginosa PBP3-β-lactam, monobactam, and DBO complexes.

open access: yes, 2021
A, vaborbactam-bound PBP3 structure with ligand in ball-and-stick representation with cyan-colored carbon atoms. The ligand’s oxygen located in the oxyanion hole (a), the carboxyl (b), the amide (c), and the five-membered thiophene (d) are labeled.
Vijay Kumar (377076)   +5 more
core   +1 more source

Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model

open access: yes, 2018
The objective of these studies was to evaluate the exposures of meropenem and vaborbactam that would produce antibacterial activity and prevent resistance development in carbapenem-resistant Klebsiella pneumoniae carbapenemase ...
Debora Rubio-Aparicio   +7 more
core   +1 more source

Vaborbactam: perspective of a new β-lactamase inhibitor in the antimicrobial chemotherapy

open access: yes, 2023
<p>Infections due to carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii constitute a global public health threat and are associated with high morbidity and mortality rates.
Koumaki, V.   +3 more
core   +1 more source

Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin

open access: yesJournal of Global Antimicrobial Resistance
Objective: A case of post-neurosurgical ventriculitis caused by a KPC-producing Klebsiella pneumoniae (KPC-Kp) with a ceftazidime/avibactam-resistant, meropenem-susceptible phenotype is reported.
Lorenzo Volpicelli   +7 more
doaj   +1 more source

Susceptibility evaluation of novel beta-lactam/beta-lactamase inhibitor combinations against carbapenem-resistant Klebsiella pneumoniae from bloodstream infections in hospitalized patients in Brazil

open access: yesJournal of Global Antimicrobial Resistance
Introduction: Novel beta-lactam/beta-lactamase inhibitor (BIBLI) combinations are commercially available and have been used for treating carbapenem-resistant Klebsiella pneumoniae (CRKP) infections.
Camila Mörschbächer Wilhelm   +16 more
doaj   +1 more source

Home - About - Disclaimer - Privacy